Abstraction Health

Tongkat Ali — Research Evidence

Source: PubMed / NCBI · human studies preferred · ranked by evidence qualityLast analyzed: May 24, 2026
Insufficient Evidence
4 studies·1 RCTs·3 reviews

The summary below was generated by an AI system (Claude) based on the studies listed. It is a synthesis tool, not a clinical opinion. Read individual studies for full context.

Tongkat Ali (Eurycoma longifolia) is a Southeast Asian root extract with a long history of traditional use for male vitality, but the current clinical evidence supporting its marketed benefits is weak to insufficient. Out of 64 expert claims evaluated against this literature, 53 were rated as having insufficient evidence, 10 as partially supported, and only 1 as fully supported. The one rigorous human trial available — a 6-month double-blind RCT in aging males with androgen deficiency — combined Tongkat Ali with concurrent exercise training, which makes it impossible to attribute any observed effects to the supplement alone. Narrative and systematic reviews offer background on traditional use and chemistry, but do not substitute for robust clinical trial data.

The most credible signal in the literature is a possible effect on testosterone levels, particularly free testosterone, in men with low androgen levels — but even this finding is only partially supported, and the evidence is not consistent across studies. Claims about erectile dysfunction improvement, muscle gain, stress reduction, and athletic performance enhancement are largely unsubstantiated in the current human research base. The existing systematic reviews on erectile dysfunction supplements flag Tongkat Ali as commonly included in products but lacking sufficient evidence to confirm efficacy.

Significant limitations constrain what can be concluded. Study populations are small and narrow (primarily aging males with clinical androgen deficiency), making findings difficult to generalize to healthy adults. The confounding effect of exercise in the primary RCT is a major methodological issue. Standardization of Tongkat Ali extracts varies across products and studies, further complicating comparisons. Much of the underlying mechanistic research is from animal or in vitro studies, which do not reliably predict human outcomes. Until larger, well-controlled human trials are conducted in diverse populations, most benefit claims remain speculative.

Key findings

  • Tongkat Ali is a root extract from Southeast Asia with centuries of traditional use for male vitality — this historical use is well-documented but does not confirm clinical efficacy.
  • The only human RCT identified was a 6-month placebo-controlled trial in aging males with androgen deficiency, but it combined Tongkat Ali with exercise training, making it impossible to isolate the supplement's effects.
  • Some evidence suggests a possible effect on free testosterone in men with low androgen levels, but this finding is only partially supported and inconsistent across studies.
  • Systematic reviews of erectile dysfunction supplements identify Tongkat Ali as commonly marketed for this purpose, but note insufficient clinical evidence to confirm benefit.
  • Out of 64 evaluated expert claims about Tongkat Ali, 83% were rated as having insufficient evidence — indicating a large gap between popular claims and actual research support.

Evidence gaps

  • ?No large, well-controlled RCTs isolating Tongkat Ali's effects (without co-interventions like exercise) in healthy or diverse adult populations exist in the current evidence base.
  • ?Long-term safety and efficacy data are lacking; most human studies are short-term and conducted in narrow populations (e.g., older males with androgen deficiency).
  • ?Extract standardization is inconsistent across commercial products and studies, making it difficult to determine what dose or formulation — if any — is effective.

Safety summary

The reviewed literature does not provide robust human safety data for Tongkat Ali, and no serious adverse events are prominently flagged in these studies, but the absence of reported harms should not be interpreted as confirmed safety given the limited trial scope and duration.

Studies (4)

Medicina (Kaunas, Lithuania) · 2022 · Leisegang K et al.
Systematic Review🟢
Key finding

COI: The authors declare no conflict of interest.
PMID: 36013514DOI: 10.3390/medicina58081047
View on PubMed

An Analysis of Popular Online Erectile Dysfunction Supplements.

The journal of sexual medicine · 2019 · Balasubramanian A et al.
Systematic Review🟢
Key finding

An Analysis of Popular Online Erectile Dysfunction Supplements.

Funded by: NIDDK NIH HHS
PMID: 31036522DOI: 10.1016/j.jsxm.2019.03.269
View on PubMed

A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM).

Maturitas · 2021 · Leitão AE et al.
RCT🟡
Key finding

A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM).

PMID: 33541567DOI: 10.1016/j.maturitas.2020.12.002
View on PubMed

Review on a Traditional Herbal Medicine, Eurycoma longifolia Jack (Tongkat Ali): Its Traditional Uses, Chemistry, Evidence-Based Pharmacology and Toxicology.

Molecules (Basel, Switzerland) · 2016 · Rehman SU et al.
Review🟡
Key finding

Review on a Traditional Herbal Medicine, Eurycoma longifolia Jack (Tongkat Ali): Its Traditional Uses, Chemistry, Evidence-Based Pharmacology and Toxicology.

Funded by: Industry (inferred from affiliations)
COI: The authors declare no conflict of interest.
PMID: 26978330DOI: 10.3390/molecules21030331
View on PubMed